Efficacy
PD, SD
DISEASE, SECONDARY
There were no objective responses to VSV-IFNβ-TYRP1 therapy. 4 patients had stable disease (SD) and 8 had progressive disease (PD) as their best response. Of the patients with initial stable disease, 1 progressed at the subsequent scan (3 months after starting treatment), and 3 patients were censored shortly after imaging because they started another line of therapy due to treating clinician discretion despite lack of progression. Next treatments after VSV-IFNβ-TYRP1 included: ipilimumab/nivolumab (Overall Survival. Median Overall Survival (OS) was 18.9 months. There were no objective responses, but efficacy was a secondary endpoint. 4 patients had stable disease and 8 patients had progressive disease. The gray zone around the curve represents the 95% confidence interval (CI).